Physician profile
Robert H Tran
NPI 1265515704
$1,586.80
in general payments reported to CMS, 2019-2025
13 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.90 · 2020: $88.05 · 2021: $198 · 2022: $99.24 · 2023: $370 · 2024: $387 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Education: $6.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.03 |
| Education | $6.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $422.24 | 2022-2025 | Dupixent |
| Genzyme Corporation | $267.67 | 2022-2025 | |
| Mirum Pharmaceuticals, INC. | $236.49 | 2022-2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $143.02 | 2025 | Bylvay |
| Abbvie INC. | $134.73 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $100.90 | 2020-2023 | |
| Travere Therapeutics, INC. | $92.50 | 2019-2023 | Cholbam |
| Albireo Pharma, INC. | $73.24 | 2023-2024 | Bylvay, Iqirvo |
| Alcresta Therapeutics, INC. | $43.13 | 2025 | Relizorb |
| Rhythm Pharmaceuticals, INC. | $27.24 | 2024 | Imcivree |
| Alfasigma USA, INC. | $17.41 | 2021 | |
| Sarepta Therapeutics, INC. | $16.20 | 2021 | |
| Aytu Biopharma, INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.